Incyte’s INCB0989 Data Shows Early Promise in Myelofibrosis, Analysts Turn Positive

Incyte’s early INCB0989 myelofibrosis data at ASH 2025 looks encouraging, prompting analyst upgrades and higher price targets from Mizuho, Wells Fargo, and Guggenheim.